AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person in recovery (Black)
Description: Exposed to a photo of a person in recovery (Black)
Study NCT06743178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a family member of an overdose decedent
Description: Exposed to a photo of a family member of an overdose decedent
Study NCT05628311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered subcutaneously (SC) once a week.
Study NCT05628311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.
Study NCT06113705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-GE-180 PET
Description: PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
Study NCT06113705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Advanced MRI
Description: MRI examination using advanced sequences to characterize tumor microstructure and function
Study NCT06113705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of hematopoietic stem cells
Description: Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
Study NCT06113705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
Study NCT06113705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of Cancer Stem Cells
Description: Glioblastoma stem cells (GSCs) will be isolated from the tumor
Study NCT06075264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate ointment
Description: topical ointment, as a non-surgical treatment
Study NCT06075264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: topical placebo ointment
Study NCT05764070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive auricular vagus stimulation
Description: The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.
Study NCT05764070 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non Invasive Vagus Stimulation
Description: Placebo Non Invasive Vagus Stimulation
Study NCT05340647 — intervention group
Intervention type: PROCEDURE
Intervention: Preserflo microshunt
Description: Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
Study NCT05340647 — intervention group
Intervention type: PROCEDURE
Intervention: Trabeculectomy
Description: Trabeculectomy surgery to lower intraocular pressure
Study NCT05340647 — intervention group
Intervention type: PROCEDURE
Intervention: Other MIGS
Description: Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
Study NCT05572216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted partial nephrectomy with 3D image guidance
Description: patient have a partial nephrectomy for renal complex tumor
Study NCT05662943 — intervention group
Intervention type: DRUG
Intervention: Intravitreal aflibercept injection
Description: Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
Study NCT04877639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmketamine,Dexmedetomidine
Description: Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
Study NCT05752331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavioural modification
Description: 8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
Study NCT05605080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelfoam
Description: Use Gelfoam as a hemostatic agent after anal surgery.
Study NCT05605080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bosmin gauze
Description: Use bosmin gauze as a hemostatic agent after anal surgery.
Study NCT06254690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib dose escalation
Description: Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study NCT06254690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib dose normal
Description: Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study NCT06547801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose
Description: 3 g/day of powder orally once daily
Study NCT06547801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 3 g/day of powder orally once daily
Study NCT05291819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging informed treat-to-target
Description: A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~* If evidence of enthesitis (power Doppler>0 in enthesis) or axial inflammation (SPARCC score ≥ 2\* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~* If evidence of ongoing inflammation (power Doppler>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target
Study NCT05291819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treat-to-target
Description: Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
Study NCT06177457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days
Study NCT06177457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days
Study NCT06177457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
Study NCT04955470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Injectable Solution
Description: A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
Study NCT04955470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Injectable Solution
Description: A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
Study NCT04955470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% Injectable Solution
Description: A 0.9% normal saline solution will be infused over a 40 minute period.
Study NCT04775004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow venting procedure (BMVP)
Description: The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
Study NCT04775004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (PRP)
Description: The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
Study NCT04242823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Automated visual evaluation
Description: Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
Study NCT06395792 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.
Study NCT06508905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep buddy
Description: The toy chosen as a sleep companion was introduced to the children in the experimental group and they were told that it would accompany them for 3 days during their hospitalization. Before giving the sleep companion, parents and children were informed about the sleep companion and their questions about the study were answered. Children who did not have their own sleep companion were included in the sample. The child was encouraged to sleep and spend time with the given sleep buddy and the family was also informed.
Study NCT05554198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attend Behavior Parent Training
Description: Attend Behavior is a Parent Training intervention available in application form for smartphones or online. Attend Behavior consists of 12 instructional modules and it is recommended that parents complete one module a week in addition to practicing the techniques taught in that course. Each learning module typically around 30 minutes to complete and includes an introductory video to give parents an overview of the different features of the application. At the start of the intervention, parents will take an assessment that will provide information for the program to create individualized goals, plans, reinforcement agents, and even daily schedules. A HIPPA compliant clinician portal within the application allows the clinician to have real time access to monitor the parent learning progress, tracked behaviors, parental notes, and message with the parent.
Study NCT06123689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMT-Regenera activa
Description: Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~1. Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~2. Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~3. The samples are processed for 6 minutes~4. The Rigeneracon is extracted from the machine.
Study NCT06123689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalubrix
Description: Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed
Study NCT05757453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Mobile platform
Study NCT06581939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Description: In the rehabilitation group, patients will follow an individualized rehabilitation program started early in the ICU and continued in the post-ICU ward then at home for 12 weeks, combining goal-directed nutrition and physical activity, tailored to gains made over time by each patient, with the involvement of dieticians, physiotherapists, and adapted-physical-activity instructors.
Study NCT06581939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In the control group, patients will receive usual care from day-0 to day-180.
Study NCT05127785 — intervention group
Intervention type: PROCEDURE
Intervention: LVAD or Heart Transplant
Description: Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
Study NCT05283707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paula Method Exercises
Description: The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
Study NCT06375876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session intervention (SSI)
Description: The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.
Study NCT05414942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid Reduction Program
Description: Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
Study NCT04621929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine / Topiramate Oral Product
Description: All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)
Study NCT04621929 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Citrate Salts, Allopurinol, Diet
Description: Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
Study NCT06105892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Eye Rotation Vision Exercise (VERVE)
Description: VERVE utilizes a virtual reality (VR) headset with integrated eye-tracking where the patient makes specific vergence eye movements by playing a VR game controlled by eye movements. Participants will be making convergence and divergence eye movements as steps and ramps.
Study NCT06105892 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR Therapy
Description: VERVE game without changes in eye movement demands. Maximizing gameplay with no intervention.
Study NCT06604598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBU-PCT-DEX
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
Study NCT06604598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBU-PCT-placebo
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
Study NCT06604598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCT-placebo-placebo
Description: Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
Study NCT05655988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: inguinal ultrasonography
Description: After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
Study NCT04774146 — intervention group
Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
Study NCT06688669 — intervention group
Intervention type: OTHER
Intervention: Fabrication of suitable complete or removable partial dentures for the patient
Description: Fabrication of suitable complete and partial dentures for the patient. The study will not interfere with this treatment process; only follow-up assessments will be conducted at specific intervals after the dentures are fabricated, and surveys will be administered to the patient.
Study NCT06691373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: Static stretching of the quadriceps and hamstrings which was performed in the dominant limb, and held in a position where the participants referred discomfort:~* Quadriceps - participants were in the standing position, with one hand holding the back of a chair to maintain the balance, and were instructed to pull the ankle of the lower limb to be stretched, pressing the heel towards the buttocks and, at the same time, extending the thigh;~* Hamstrings - participants were also in the standing position, with the heel resting on a chair. They were then instructed to lean the body forward keeping the spine erect and the pelvis in anteversion, to obtain a stretch over the knee and hip.
Study NCT06689644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
Description: Commercially available product: Mind lab pro
Study NCT06689644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A cellulose commonly used as a bulking agent in supplement products
Study NCT06689644 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Perceptual decision-making performance
Description: A computerised cognitive task involving rapid visual categorisation of images
Study NCT06689644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual decision-making performance
Description: A computerised cognitive task involving rapid visual categorisation of images
Study NCT06689644 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroencephalography
Description: Brain signals are recorded from a 64 channel EEG system during the cognitive task
Study NCT06689644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Brain signals are recorded from a 64 channel EEG system during the cognitive task
Study NCT05268237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Sublingual or subcutaneous liraglutide
Study NCT05268237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual placebo
Study NCT06491667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
Study NCT06138080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography
Description: We have no specific intervention. We investigate different diagnostic modalities of VUR.
Study NCT06545955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadofaragene Firadenovec
Description: vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
Study NCT06545955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
Study NCT06545955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
Study NCT06545955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
Study NCT06491667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
Study NCT05397405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months